Loading…
SARMs Control Act of 2018
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,805 other S bills in the 115th — cohort avg 41d
Selective Androgen Receptor Modulators Control Act of 2018 or the SARMs Control Act of 2018 This bill amends the Controlled Substances Act (CSA) to add SARMs (selective androgen receptor modulators) to schedule III. A SARM is a synthetic drug or substance that has effects similar to testosterone. A schedule III controlled substance (e.g., an anabolic steroid) has less potential for abuse than a schedule I or II substance, has a currently accepted medical use, and has low or moderate risk of dependence if abused. The bill also: authorizes, and establishes procedures for, the Drug Enforcement Administration (DEA) to temporarily and permanently add a drug or substance to the definition of a SARM; specifies that a felony drug offense includes an offense related to SARMs; and makes it unlawful to import, export, manufacture, distribute, dispense, or possess with intent to manufacture, distribute, or dispense, a SARM that is not clearly labeled. The bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration to notify the DEA when it determines that a new dietary ingredient in a dietary supplement may contain a SARM or SARM analogue.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2018 · fourth_quarter · Pharmacy
Educate policymakers about targeted hormone receptor-based therapies and monitor related legislation, including S. 2742, the SARMS Control Act of 2018.
Client expense: Not reported · Firm income: $90,000
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Trade (domestic/foreign)
S. 2742 - Selective Androgen Receptor Modulators (SARMs) Control Act, a bill to amend the Controlled Substances Act to more effectively regulate selective androgen receptor modulators; all provisions relating to dietary supplements
Client expense: $120,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Health Issues
Monitor the following: HSA and FSA -- Dietary supplement issues S.2742, SARMS Control Act of 2018, generally
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Pharmacy
Educate policymakers about targeted hormone receptor-based therapies and monitor related legislation, including S. 2742, the SARMS Control Act of 2018.
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Health Issues
Monitor the following: H.R.1175/S.403, Health Savings Act of 2017, Monitor HSA and FSA -- Dietary supplement issues S.2742, SARMS Control Act of 2018, generally
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · third_quarter · Trade (domestic/foreign)
S. 2742 - Selective Androgen Receptor Modulators (SARMs) Control Act, a bill to amend the Controlled Substances Act to more effectively regulate selective androgen receptor modulators; all provisions relating to dietary supplements
Client expense: $150,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Pharmacy
Educate policymakers about targeted hormone receptor-based therapies and monitor related legislation, including S. 2742, the SARMS Control Act of 2018.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
Educate policymakers about targeted hormone receptor-based therapies and monitor related legislation, including S. 2742, the SARMS Control Act of 2018.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Trade (domestic/foreign)
S. 2742 - Selective Androgen Receptor Modulators (SARMs) Control Act, a bill to amend the Controlled Substances Act to more effectively regulate selective androgen receptor modulators; all provisions relating to dietary supplements
Client expense: $190,000 · Firm income: Not reported
Government targets: Drug Enforcement Administration (DEA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Health Issues
H.R.1175/S.403, Health Savings Act of 2017, Monitor HSA and FSA -- Dietary supplement issues S.2742, SARMS Control Act of 2018, generally
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE